樂普醫療(300003.SZ)：擬以2.37億元取得博思美68.4318%的股權 進入口腔正畸領域
格隆匯7月16日丨樂普醫療(300003.SZ)公佈，公司於2021年7月14日召開第五屆董事會第二十一次會議，審議通過《關於投資蘇州博思美醫療科技有限公司》的議案。
公司擬以人民幣23729.619萬元通過股權受讓和增資方式投資蘇州博思美醫療科技有限公司(“博思美”)68.4318%的股權，實現控股。
博思美是一家提供牙齒畸形矯正解決方案與定製生產隱形矯治器的高科技公司。為滿足不同人羣的需求，博思美推出了適用於成人的“Bonsmile隱形正畸系列”和“iBeatuy隱形正畸系列”，以及針對兒童錯頜畸形的“iFree兒牙早矯系列”，建立了覆蓋全年齡段全週期的隱形矯治產品線。
“iFree兒牙早矯系列”是博思美聯合國內頂尖口腔正畸學教授研發的“地包天”超早期快速隱形矯治系統，該技術突破了兒童早期矯治中矯治固位難、在上頜骨前牽引發育階段同時對上下牙進行三維調整移動的兩大技術瓶頸，可覆蓋4-15歲兒童早期矯治所有的病例解決方案。“iFree兒牙早矯系列”已申請8項專利，填補了國內該領域的技術空白，具有巨大的市場潛力。
牙頜畸形是繼齲病、牙周病之後口腔的第三大疾病，根據2017年9月發佈的《第四次全國口腔健康流行性病學調查報吿》顯示，中國錯頜畸形發病率達到70%以上，兒牙畸形發病率在80%。牙頜畸形影響牙齒健康和口腔功能，“顏值經濟”喚醒護牙需求，口腔正畸行業未來發展潛力巨大。
口腔正畸兼具醫療治療和醫療消費雙重屬性，相較於傳統的託槽矯治，無託槽隱形矯治在舒適度、美觀度、衞生健康、治療週期等方面優勢明顯，將更受消費者青睞。2020年我國310萬正畸案例中，隱形正畸的滲透率僅為11%，隨着全科牙科醫生使用率的提升以及產品線的豐富，隱形正畸行業正處於黃金髮展階段。
公司通過控股博思美進入口腔正畸領域，是公司積極拓展醫療消費領域的戰略性投資，此次投資能夠充實公司類消費醫療產品線，是公司實施培育和發展類消費器械、健康產品產業發展戰略邁出的堅實一步。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
